Michael Polansky is training an AI model on skin that's still alive
Outer Biosciences, founded in 2022 by Michael Polansky, has developed a platform to keep living human tissue alive outside the body for over a month, addressing a critical bottleneck in biological research The company sources discarded human skin (primarily from plastic surgery) through vetted biobanks operating under IRB oversight and documented donor consent, receiving tissue within hours of surgery while still viable The core problem addressed is that biological and chemical innovation lags f
Analysis
TL;DR
- Outer Biosciences, founded in 2022 by Michael Polansky, has developed a platform to keep living human tissue alive outside the body for over a month, addressing a critical bottleneck in biological research
- The company sources discarded human skin (primarily from plastic surgery) through vetted biobanks operating under IRB oversight and documented donor consent, receiving tissue within hours of surgery while still viable
- The core problem addressed is that biological and chemical innovation lags far behind software because ethical constraints prevent direct human experimentation, and existing proxies—animal models, simplified cell cultures, and lab-grown organoids—are poor stand-ins for real human organ behavior
- Polansky's background spans applied mathematics and computer science (Harvard, 2006), hedge fund management at Bridgewater Associates, and a principal role at Founders Fund before transitioning into life sciences through Sean Parker's cancer immunotherapy initiatives
- Lady Gaga (Stefani Germanotta) sits on Outer Biosciences' board, and the two companies collaborate at the margins, with shared scientific advisory overlap
Why It Matters
Outer Biosciences represents a potentially transformative approach to bridging the gap between computational and biological innovation by creating human-relevant in vitro models that could accelerate drug discovery, reduce reliance on animal testing, and improve clinical trial outcomes. For AI and biotech practitioners, this highlights the growing convergence of computational thinking with experimental biology—Polansky's math and CS background is directly applicable to scaling biological research pipelines.
Technical Details
- Tissue sourcing pipeline: The company spent approximately two years building a supply chain to receive living human tissue within hours of surgical discard, working through the National Disease Research Interchange and the Cooperative Human Tissue Network—NIH- and NCI-funded biobank brokers operating under IRB oversight
- Donor consent and de-identification: All tissue samples arrive de-identified upstream; the company pays cost-recovery fees rather than purchasing tissue outright, navigating a fragmented regulatory landscape with no single government tissue network qualifying buyers
- Long-term tissue viability: The proprietary capability centers on maintaining living human tissue ex vivo for extended periods (over a month), enabling repeated experimentation on human-relevant biological material
- Inter-company collaboration: Outer Biosciences' chief scientist, Kyung-Jin Jang, sits on Haus Labs' scientific advisory board, creating a cross-pollination channel between cosmetics R&D and human tissue modeling
Industry Insight
- The human tissue-in-a-dish approach could become a critical infrastructure layer for the growing AI-for-biology sector, providing high-fidelity training and validation data that animal models and cell lines cannot match—companies that secure early access to such platforms will have a significant R&D advantage
- The regulatory and sourcing complexity (IRB oversight, donor consent, multi-biobank coordination) represents a substantial moat; competitors will face similar multi-year pipeline-building challenges, making first-mover advantage meaningful
- The Polansky-Germanotta partnership illustrates a broader trend of celebrity-backed biotech ventures combining cultural capital with scientific ambition—this model may accelerate funding and talent acquisition but also introduces unique governance and public-scrutiny dynamics that founders should plan for
Disclaimer: The above content is generated by AI and is for reference only.